arrow
Y

Young Kul Jung

university of ulsan
H指数:32
被引数:3,969

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB

Tenofovir Alafenamide 与 Tenofovir Disoproxil Fumarate 在降低 CHB 患者肝癌发生风险方面的比较

2026-03-080
PRE
Enhanced pathogen detection and gut microbiome alterations in pyogenic liver abscess: insights from next-generation sequencing

脓毒性肝脓肿中增强的病原体检测和肠道微生物组改变:来自下一代测序的见解

2026-02-160
OAAI
Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection

人类免疫缺陷病毒/丙型肝炎病毒混合感染的最佳时辰治疗效果与丙型肝炎病毒单一感染相似

2026-01-210
PRE
Temporal Dynamics and Treatment Outcomes of Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: A Multicenter Retrospective Study from South Korea

丙型肝炎病毒/人类免疫缺陷病毒合并感染的时间动力学和治疗结果: 来自韩国的多中心回顾性研究

2025-11-010
OAAI
Effect of diabetes on mortality and liver transplantation in alcoholic liver cirrhotic patients with acute decompensation
2024-07-170
PRE
Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment
2024-07-013
OAAI
Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort
2024-05-081
PRE
A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study (VOL 119, 1706, 2024)
2024-03-040
PRE
New prognostic model for hospitalized patients with alcoholic cirrhosis and Maddrey's discriminant function <32

酒精性肝硬化住院患者的新预后模型和Maddrey判别函数 <32

2023-10-130
PRE